Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients: a Multicenter, Double-blind, Placebo-controlled, Randomized Study

NCT06964815 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT06964815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06964815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients: a Multicenter, Double-blind, Placebo-controlled, Randomized Study
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Not applicable
Overall status
Withdrawn
Start date
November 12, 2025
Completion date
October 31, 2027
Enrollment
0 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, idh wild-type and stat3-positive glioblastoma